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Abstract Inhibition of osteoblast-mediated mineralization is one of the major catabolic effects of parathyroid
hormone (PTH) on bone. Previously, we showed that PTH induces matrix g-carboxyglutamic acid (Gla) protein (MGP)
expression and established that this induction is critical for PTH-mediated inhibition of osteoblast mineralization. In the
present study, we focus on themechanism throughwhich PTH regulatesMGP expression in osteoblasticMC3T3-E1 cells.
Following transient transfection of these cells with a 748 bp murine MGP promoter-luciferase construct (pMGP-luc),
PTH (10 7 M) induced promoter activity in a time-dependent manner with a maximal four- to six fold induction seen 6 h
after PTH treatment. Both H-89 (PKA inhibitor) and U0126 (MEK inhibitor), suppressed PTH induction of MGP promoter
activity as well as the MGP mRNA level. In addition, forskolin (PKA activator) stimulated MGP promoter activity and
mRNA levels confirming that PKA is one of the signaling molecules required for regulation of MGP by PTH. Co-
transfection of MC3T3-E1 cells with pMGP-luc and MEK(SP), a plasmid encoding the constitutively active form of MEK,
led to a dose-dependent increase in MGP promoter activity. Both MGP promoter activity andMGPmRNA level were not
affected by the protein kinase C (PKC) inhibitor, GF109203X. However, phorbol 12-myristate 13-acetate (PMA), a
selective PKC activator inducedMGPmRNA expression through activation of extracellular signal-regulated kinase (ERK).
Taken together, these results indicate that PTH regulates MGP via both PKA- and ERK-dependent pathways. J. Cell.
Biochem. 102: 496–505, 2007.  2007 Wiley-Liss, Inc.
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Parathyroid hormone (PTH) functions as a
key regulator of calcium homeostasis by acting
through its target organs, that is, bone, kidney,
and intestine, to increase serum calcium levels.
In bone, PTH serves as amajormediator of bone
remodeling. The in vivo effects of PTH on bone
canbe either anabolic or catabolic, dependingon
dosage, method of delivery, and frequency of
treatment [Tam et al., 1982]. Intermittent low
dose administration of PTH in vivo promotes
bone formation while continuous treatment
results in bone loss [Ishizuya et al., 1997; Jilka
et al., 1999]. Continuous exposure to PTH
in vitro has been shown to inhibit osteoblast
differentiation and mineralization in primary
calvarial osteoblasts, calvarial explants, and
osteoblast-like cell lines [Bellows et al., 1990;
Pfeilschifter et al., 1990; Ishizuya et al., 1997;
Koh et al., 1999; Wang et al., 2000].
In osteoblasts, actions ofPTHaremediatedby
thePTH1receptor (PTH1R), a seven transmem-
brane domain G-protein coupled receptor
expressed on the cell surface. PTH treatment
is known to stimulate three major signaling
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cascades leading to activation of protein kinase
A (PKA), protein kinase C (PKC), and extra-
cellular signal-regulated kinase (ERK) path-
ways [Partridge et al., 1994; Swarthout et al.,
2002]. Following activation of these signaling
pathways, PTH regulates its target genes
by activation of several transcription factors
[Partridge et al., 1994]. The cAMP response
element binding protein (CREB), activator
protein-1 (AP-1) transcription factors, and
RUNX2 are among the most widely studied
PTH-responsive transcription factors in osteo-
blasts. Post-translational modifications such
as phosphorylation are required for activation
of these transcription factors, which in turn
regulate changes in gene expression.
Matrix g-carboxyglutamic acid (Gla) protein
(MGP) is a vitamin K-dependent protein found
in hypertrophic chondrocytes, cementum, vas-
cular smooth muscle cells, and bone [Price,
1989; Sato et al., 1998]. MGP is produced by a
variety of cell types in culture, including osteo-
blasts, chondrocytes, vascular smooth muscle
cells, and endothelial cells [Fraser et al., 1988;
Barone et al., 1991; Engelse et al., 2001;
Gopalakrishnan et al., 2001]. MGP functions
as an inhibitor of mineralization both in vitro
and in vivo [Luo et al., 1997]. Retrovirus-
mediated overexpression of MGP greatly
decreased mineralization in cultured chondro-
cytes and inhibited cartilage mineralization as
well as endochondral ossification in developing
chick limb bud [Yagami et al., 1999]. Major
in vivo evidence that further substantiates the
role ofMGPas a potentmineralization inhibitor
comes from studies in MGP-deficient mice.
These mice exhibit abnormal calcification of
cartilage and extensivemineralization of arteri-
es [Luo et al., 1997]. Mutation of the MGP gene
in humans results in Keutel syndrome, an
autosomal recessive disorder characterized by
abnormal cartilage calcification, peripheral
pulmonary stenosis, and midfacial hypoplasia
[Munroe et al., 1999].
Although several studies have been pub-
lished, investigating the regulation of MGP
expression in chondrocytes, vascular smooth
muscle cells, and endothelial cells by several
growth factors and hormones such as retinoic
acid, TGFb, FGF2, and thyroid hormone
[Cancela and Price, 1992; Kirfel et al., 1997;
Stheneur et al., 2003; Sato et al., 2005], notmuch
is known about regulation of MGP in osteo-
blasts. Previously, we showed that MC3T3-E1
osteoblast-like cells express MGP, and PTH
treatment induces MGP mRNA level in a time-
and dose-dependent manner [Gopalakrishnan
et al., 2001]. We also showed that MGP is a key
regulator in PTH-mediated inhibition of miner-
alization in these cells. To further understand
the mechanism by which PTH regulates MGP
expression in osteoblasts, we investigated the
signaling pathways involved in PTH regulation
of MGP mRNA level and promoter activity in
MC3T3-E1 cells. Our studies show that actions
of PTH on MGP can be explained, at least in
part, by stimulation of MGP promoter activity.
Furthermore, this activation is mediated by
both PKA- and ERK/MAPK pathways.
EXPERIMENTAL PROCEDURES
DNA Constructs
The murineMgp promoter construct, pMGP-
luc, containing bases 748 to þ1 of the murine
Mgp gene was derived from pMGP2 and
subcloned into the HindIII site of pGL3Basic
(Promega, Madison, WI) upstream of the firefly
luciferase reporter gene. The plasmid pMGP2
was a gift from Dr.Gerard Karsenty (Baylor
University, Houston, TX) [Luo et al., 1995].
pCMV5-MEK(SP), a plasmid encoding consti-
tutively active mutant of MEK, was kindly
provided by Dr. Kun-Liang Guan (University of
Michigan, Ann Arbor, MI) and was used as
described previously [Xiao et al., 2000].
Cell Culture
A highly differentiating subclone of MC3T3-
E1 cells (MC-14) was used for the studies [Wang
et al., 1999; Petryk et al., 2005].MC3T3-E1 cells
express most of the known osteoblast markers
and form a mineralized ECM following differ-
entiation inAA-containingmedium.MC3T3-E1
cells were maintained in MEM media contain-
ing 10% FBS, 1% penicillin/streptomycin, 1%
non-essential amino acids, and were not used
beyond passage 20. For all experiments except
those involving transfection, cells were plated
at 50,000 cells/cm2 and treatments performed in
0.1% FBS containingMEM. Experiments invol-
ving signaling inhibitors were pretreated for
30 min with signaling inhibitors. The following
specific activators and inhibitors for each
signaling pathway were used; PKA inhibitor
(H-89); PKC inhibitors (GF109203X); MEK/
ERK inhibitors (U0126); PKA activators
(forskolin and 8-Br cAMP); and PKC activator
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[phorbol 12-myristate 13-acetate (PMA)]. For
experiments involving transfection, MC3T3-E1
cells were plated at a density of 25,000 cells/cm2
in 35-mm dishes.
Western Blot Analysis
MC3T3-E1 cells were serum starved for 24 h,
following which cells were pretreated with
the indicated concentration of GF109203X or
U0126 for 30 min in AA-free MEM containing
0.1% FBS. After 30 min, PMA or DMSO as
control, were added in the media for 10 min.
Whole cell extracts were harvested in 1X
lysis buffer [100mM tris(hydroxymethyl)ami-
nomethane (Tris, pH 7.4), 100mM NaCl, 1mM
ethylenediamine-tetra acetic acid (EDTA),
1mM ethyleneglycol-tetra acetic acid (EGTA),
1mM NaF, 20 mM NaP2O4, 2mM Na3VO4, 1%
Triton X-100, 10% glycerol, 0.1% sodium dode-
cyl sulfate (SDS), 0.5% deoxycholate, 1mM
PMSF, and protease inhibitors (protease inhi-
bitor cocktail tablets, Boehringer Mannheim,
1 tablet/10ml]. Proteins were separated by 12%
SDS–PAGE and transferred to a PVDF mem-
brane (Millipore, Billerica, MA). Immunoblot-
ting was performed as previously described
[Petryk et al., 2005], with anti-total ERK 1/2
and phosphorylated ERK1/2 antibodies and
horseradish peroxidase-conjugated secondary
antibodies. Immunoreactive bands were then
visualized by chemiluminescence using ECLkit
(Amersham Pharmacia Biotech).
RNA Isolation and Northern Blot Analysis
Total RNA was extracted using TRIzol reag-
ent (Invitrogen Life Technologies, Carlsbad,
CA) according to manufacturer’s directions
and quantified by UV spectrophotometry.
Northern blot analysis was performed as pre-
viously described [Gopalakrishnan et al., 2001;
Petryk et al., 2005]. Fifteen microgram aliquots
of total RNAwere fractionated on 0.8% agarose-
formaldehyde gels, transferred to nitrocellulose
membranes and UV cross-linked. MGP cDNA
was obtained fromDr. GerardKarsenty (Baylor
College of Medicine, Houston, TX) [Luo et al.,
1995]. The membrane was hybridized with a
32P-labeled mouse MGP cDNA probe label-
ed with [a-32P]deoxy-CTP (Amersham Bio-
sciences/GE Healthcare, Piscataway, NJ) using
a random primer labeling kit (Invitrogen Life
Technologies). All blots were normalized for
RNA loading by stripping and reprobing with
cDNA to 18S rRNA [Renkawitz et al., 1979].
Real-Time RT-PCR
Reverse transcription of extracted mRNA
was performed using 1 mg of denatured RNA
and 100 pmol of random hexamers (Invitrogen
Life Technologies) in a 20 ml total volume
containing 50 U Super Script reverse transcrip-
tase (Invitrogen Life Technologies). Quantita-
tive RT-PCR was performed as previously
described using MX MX 3000PTM real-time
PCR System (Stratagene Corporation, La Jolla,
CA) using 1 ml of the cDNA equivalent to 50 ng
mRNA with 1x Brilliant SYBR Green master
mix andROX reference dye (1:500) (Stratagene,
La Jolla, CA) [Gopalakrishnan et al., 2005]. The
final reaction volume was 25 ml, and each
sample was run in duplicates for both MGP
and GAPDH, which was used as a house
keeping gene. MGP primer sequences were
used as previously published [Newman et al.,
2001]. The mRNA levels were normalized by
usingmouseGAPDHas housekeeping gene and
compared with levels of mouse total RNA
(Stratagene). The fold change was calculated
using the control sample Ct values at each
specified time point as a calibrator by means
of 2DDCT method.
Transfection and Luciferase Activity Assay
Twenty-four hours after plating, MC3T3-E1
cells were co-transfected, using Lipofectamine
(Invitrogen, Carlsbad, CA), with 1 mg/dish of
pMGP-luc promoter construct and 0.05 mg/dish
of pRL-SV40 Renilla luciferase vector (Pro-
mega) for normalization of transfection. Four
hours later, transfection media was replaced
by MEM containing 10% FBS overnight. The
following day, cells were treated with vehicle,
PTH (107 M) or signaling activators in MEM
containing 0.1% FBS. In experiments using
signaling inhibitors, cells were pretreated with
signaling inhibitors or DMSO for 30 min
followed by vehicle or PTH (107 M) treatment.
For overexpression of MEK(SP), cells were co-
transfected with 1 mg/dish of pMGP-Luc pro-
moter construct and 0.1–0.5 mg/dish of pCMV-
MEK(SP) plus 0.05 mg/dish of pRL-SV40Renilla
luciferase vector (Promega) for normalization
of transfection. Four hours later, transfection
media was replaced by MEM containing 10%
FBS. Cell lysates were harvested 48 h after
transfection. Luciferase activity in cell lysates
were assayed using the Dual Luciferase Repor-
ter kit (Promega) and EG&G Berthold Lumat
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LB9507 luminometer according to the manu-
facturer’s instruction.
Statistical Analysis
All transfection experiments were performed
in triplicate and repeated at least three times.
Data represented as meanSD will be ana-
lyzed using Student t-test or one-way ANOVA
followed by Tukey–Kramer multiple compar-
ison test to determine significance between
groups.
RESULTS
PTH Induction of Mgp Promoter Activity
Prior to a more detailed analysis of the PTH-
responsive elements in the Mgp promoter, we
investigated whether PTH can affect Mgp
promoter activity. A 748 bp portion of the
Mgp promoter was previously shown to be
transcriptionally activewhen transiently trans-
fected into MGP-expressing UMR106-01 cells,
but was not active in a lymphocyte cell line that
does not express MGP [Luo et al., 1995]. In
addition, this promoter fragment contains suffi-
cient information for transcriptional activation
by FGF2 in proliferative chondrocytes [Sthe-
neur et al., 2003]. To evaluate actions of PTH on
this promoter, pMGP-Luc plasmid was transi-
ently transfected into MC3T3-E1 cells followed
by treatment with vehicle or PTH (107M). As
expected, PTH treatment induced the 748 bp
Mgp promoter activity in MC3T3-E1 cells in a
time-dependent manner with approximately
threefold induction seen after 3 h (Fig. 1). The
maximal induction was approximately four- to
sixfold at 6 h after treatment and the activity
gradually declining to baseline levels by 24 h.
We also found that PTHdoes not have any effect
on the activity of pGL3Basic empty vector (data
not shown).
PTH Induction of MGP Promoter Activity
and MGP mRNA Requires PKA and
ERK/MAPK Pathways
To identify the signaling pathways involved
in PTH regulation of MGP, we used specific
inhibitors for the three signaling pathways
known to be activated by PTH, that is, PKA,
PKC, and ERK pathways. Appropriate dosages
of each inhibitor were established using Wes-
tern blot analysis of the phosphorylation of
known target proteins. For these studies, we
measured H-89 inhibition of PKA-dependent
phosphorylation of CREB with or without PTH
stimulation, GF109203X inhibition of PKC-
dependent ERK1/2 phosphorylation (using
PMA as inducer) and U0126 inhibition of FBS
induction of MEK-dependent ERK1/2 phos-
phorylation (data not shown). For each inhibi-
tor, the minimal effective dose to inhibit target
protein phosphorylation was chosen for the
experiments to investigate the signaling path-
ways involved in MGP induction by PTH.
As shown in Figure 2A, H-89, a PKA-specific
inhibitor, dramatically inhibited PTH-induced
MGP promoter activity in a dose-dependent
manner (1–10 mM). Similar resultswere obtain-
ed with U0126, an ERK inhibitor, although
inhibitionwas less-complete than that for H-89.
In contrast, the PKC inhibitor, GF109203X
(0.1–1 mM) did not have a significant effect on
the PTH-inducedMGP promoter activity. Simi-
lar results were obtained when MGP mRNA
were measured by Northern blot (Fig. 2B) and
real-time RT-PCR analysis (Fig. 2C). H-89
(10 mM) and U0126 (10 mM) inhibited MGP
induction of mRNA expression following PTH
treatment.However, GF109203X (1 mM), aPKC
inhibitor failed to inhibit PTH induction ofMGP
mRNA expression. These results suggest that
PKA and ERK-pathways are more likely
involved in PTH regulation of MGP expression.
Activation of PKA and ERK Pathways Induced
MGP mRNA and MGP Promoter Activity
To confirm the inhibitor studies, we used
activators of signaling pathways to induceMGP
Fig. 1. Effect of PTH (1–34) on748 bpMgp promoter activity.
MC3T3-E1 cells were co-transfected with 0.05 mg pRL-SV40 and
1mg pMGP-lucusing lipofectamine and treatedwith PTH (107M)
or vehicle in MEM containing 0.1% FBS for the indicated time.
Data represent relative fold induction compared with vehicle-
treated group. Error bars represent standard deviation. **, P<
0.01 (significantly different from vehicle treated group).
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expression and promoter activity. We found
that PKA activators, forskolin (1 mM) and 8-Br
cAMP (3 mM), induced MGP promoter activity
up to sixfold (Fig. 3A). Forskolin also induced
MGP mRNA expression as shown by both
Northern blot and real-time RT-PCR analysis
(Fig. 3B,C). Activation of the ERK pathway was
achieved by overexpressing pCMV-MEK(SP), a
plasmid encoding a constitutively active form of
MEK, in MC3T3-E1 cells co-transfected with
pMGP-luc. In these cells, MGP promoter activ-
ity was induced in a dose-dependent manner
Fig. 2. PKA and ERK but not PKC inhibitors blocked PTH
induction ofMGP.A: MC3T3-E1 cells were transfectedwith 1 mg
pMGP-luc using lipofectamine and treatedwith PTH (107M) or
vehicle in MEM containing 0.1% FBS in the presence of varying
concentrations ofH-89,GF109203X,orU0126 for 6h.All values
are represented as mean SD from triplicate samples. B:
Northern blot analysis and (C) real-time RT-PCR analysis of
MGP mRNA expression following treatment with PTH in the
presence or absence of inhibitors of PKA (H-89), PKC
(GF109203X), andMAPK (U0126) pathways inMC3T3-E1 cells.
Real-timeRT-PCR values aremean SD from three independent
experiments. *, P<0.05; ***P<0.001 (a, significantly different
than vehicle treated group; b, significantly different from PTH
group).
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(Fig. 4) indicating that the ERK pathway is
involved in regulation of MGP transcription.
Activation of PKC Pathway Induced MGP mRNA
but not MGP Promoter Activity
The inhibitor studies in Figure 2A,B showed
that GF109203X did not affect PTH-induced
MGP mRNA or promoter activity. Consistent
with the inhibitor studies, activation of PKC
pathway by PMA (10 mM) does not have a
significant effect on the MGP promoter activity
(Fig. 3A). However, PMA (10 mM) surprisingly
increased MGP mRNA expression comparable
to that induced by forskolin (Fig. 3B).
PKC Activation Stimulates ERK1/2
Phosphorylation in MC3T3-E1 Cells
Evaluation of ERK1/2 activation by PMAwas
performed to explain a possible mechanism for
induction of MGP mRNA expression by PMA.
Recent reports have suggested that PTH signal-
ing in osteoblasts involved cross-talk between
multiple pathways [Swarthout et al., 2002].
Further, it has been reported that PTH treat-
ment stimulated ERK activity in UMR-106
osteoblastic cells and this activation is PKC-
dependent [Swarthout et al., 2001]. Here we
show that PMA-mediated activation of PKC
pathway inMC3T3-E1 cells stimulated ERK1/2
phosphorylation (Fig. 5B). GF109203X dose-
dependently inhibited PMA-induced ERK1/2
phosphorylation suggesting that PMA-medi-
ated ERK phosphorylation is dependent on
one or more conventional PKC isozymes,
that is, PKC alpha, betaI, betaII, and gamma
(Fig.5B). U0126, a specific MEK inhibitor, also
reducedPMA-inducedERK1/2 phosphorylation
suggesting that MEK is also involved in PMA-
induced ERK1/2 phosphorylation (Fig. 5C). To
confirm whether MGP mRNA induction by
PMA is mediated by ERK1/2 phosphorylation,
we quantitatedMGPmRNA expression by real-
time RT-PCR analysis following co-treatment
with PMA (10 mM) and U0126 (1–10 mM). As
shown in Fig. 5A, U0126 significantly inhibited
PMA-mediated induction of MGP mRNA
expression in MC3T3-E1 cells. Therefore, we
conclude that PMA activation of MGP mRNA
expression is most likely mediated through
ERK1/2 phosphorylation.
Fig. 3. A: PKA but not PKC activators induced MGP promoter
activity. MC3T3-E1 cells were treated with vehicle, 1 mM
forskolin, 3 mM 8-Br cAMP,or 10 mM PMA in MEM containing
0.1% FBS for 6 h. All values are the mean SD of triplicate
samples. Northern blot analysis (B) and real-time RT-PCR
analysis (C) of MGP mRNA expression in MC3T3-E1 cells
following treatment with DMSO, 1 mM forskolin or 10 mM PMA.
Real-timeRT-PCR values aremean SD from three independent
experiments. *, P< 0.05; **, P< 0.01 (significantly different from
vehicle-treated group).
Fig. 4. ERK pathway activation dose-dependently induced
MGP promoter activity. MC3T3-E1 cells were co-transfected
with 1 mg pMGP-luc and 0.1-0.5 mg pCMV-MEK(SP). Cell lysates
were harvested 48 h after transfection. Data represent relative
fold induction compared with pCMV-bgal group. Error bars
represent standard deviation. **, P< 0.01 (significantly different
from control group).
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DISCUSSION
In this study, we identify PKA and ERK as
two signaling pathways involved in PTH reg-
ulation of MGP. Inhibition of PKA or ERK
pathways drastically decreased PTH-induced
MGP promoter activity as well as MGP mRNA
expression. However, PKA appeared to be the
primary pathway in this regulation, because
MGP induction by PTH is more sensitive to
H-89 than to the MEK inhibitor U0126, when
used at their optimal doses. We also confirmed
the results of these inhibitor studies by using
selective signaling pathway activators. Stimu-
lation of either PKA or ERK pathways drama-
tically increased MGP promoter activity. These
results suggest the involvement of these two
pathways in transcriptional regulation of MGP
by PTH.
PKA has long been known as the major
signaling pathway mediating most of biological
effects of PTH [Swarthout et al., 2002]. Two
activators of the PKA pathway, forskolin and
8-Br cAMP, were used in the current study.
While forskolin directly activates adenylyl
cyclase and thus raises cAMP level, 8-Br cAMP
activates PKA by acting as a cAMP agonist
[Insel and Ostrom, 2003]. We have shown that
both forskolin and 8-Br-cAMP activate the
pMGP-luc promoter. Our study also shows that
forskolin increases MGP mRNA by approxi-
mately twofold. This result suggests that the
inductive effect of PTH on MGP is, at least
partially, PKA-dependent.
One of the consequences of PTH receptor
activation is the production of diacylglycerol
(DAG) which leads to activation of PKC
[Civitelli et al., 1988; Civitelli et al., 1989;
Dunlay and Hruska, 1990]. PMA can directly
activate PKC by acting as a DAG analog. Here
we show that PKC inhibition or activation does
not have any effect on PTH-induced MGP pro-
moter activity. However, we found that PMA
treatment induces MGP mRNA levels compar-
able to forskolin treatment suggesting thatPKC
may be involved in MGP expression. Atleast
two reasons can be proposed to explain why the
PKC inhibitor, GF109203X, did not block PTH
induction ofMGPmRNAand promoter activity,
while PMA activated only MGP mRNA expres-
sion, but not the MGP promoter activity. First,
eleven different isozymes of PKC, alpha, betaI,
betaII, gamma, delta, epsilon, nu, lambda(iota),
mu, theta, and zeta, have been identified
[Liu and Heckman, 1998]. GF109203X inhibits
only conventional PKC isozymes, that is, alpha,
betaI, betaII, and gamma. However, PMA
stimulates most of the isozymes except PKC
zeta andPKC lambda [Liu andHeckman, 1998].
PTH on the other hand activates alpha, beta I,
and delta [Dossing et al., 2001; Radeff et al.,
2001; Erclik andMitchell, 2002]. Therefore, it is
possible that the inductive effect of PMA and
PTH on MGP mRNA level is mediated through
PKC isozyme(s) other than those inhibited by
GF109203X. Second, induction of MGP expres-
sion by PMA maybe regulated at the post-
transcriptional level, possibly by the stabiliza-
tion of MGP mRNA, or by slowing down MGP
mRNA degradation. Further, the inability of
Fig. 5. PKC activation stimulates ERK1/2 phosphorylation in
MC3T3-E1 cells through MEK. A: Real-time RT-PCR analysis
showing MGP mRNA levels following treatment with PMA (10
mM) and various doses of U0126 in MC3T3-E1 cells. All values
are mean SD from three independent experiments. B: Western
blot analysis of pERK1/2 following treatment with PMA (10 mM)
alone or in the presence of various doses GF109203X inMC3T3-
E1 cells.C:Western blot analysis of pERK1/2 following treatment
with PMA (10 mM) alone or in the presence of various
concentrations of U0126. *, P<0.05; **, P< 0.01. (a, Signifi-
cantly different than vehicle-treated group; b, significantly
different from PMA-treated group).
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PMA to activate the748 bpMGP promoter, in
spite of inducingMGPmRNA expression, could
possibly be due to the absence of necessary
promoter elements in the analyzed pMGP-luc.
A larger 5 kb promoter fragment can be utilized
to further evaluate the regulatory elements
involved in PKC activation of MGP.
In addition to PKA and PKC, the ERK
pathway has recently been shown to be stimu-
lated by PTH. Swarthout et al. [2001] reported
that ERK activity is induced only by low (1012
to 1011 M) but not high (108 M) doses of PTH
in UMR106 rat osteoblastic cells. In these cells,
activation of ERK by PTH is MEK- and PKC-
dependent. Here, we found that U0126 inhibits
PTH-induced MGP mRNA expression and pro-
moter activity inMC3T3-E1 cells. Furthermore,
we also show that ERK activation by pCMV-
MEK(SP) significantly induces MGP promoter
activity, thereby suggesting a direct role for the
ERK pathway in MGP regulation.
To further understand the mechanisms by
which PTH or PMA induces MGP expression,
we chose to investigate the connection between
the PKC and ERK pathways. Based on our
results, we speculate that ERK1/2 phosphoryla-
tion might be involved in MGP induction
following PKC activation in MC3T3-E1 cells.
As shown in Figure 5, PMA-mediated PKC
activation induces MGP mRNA expression and
U0126 inhibits this induction, suggesting that
ERK phosphorylation is required for PKC-
mediatedMGP induction.Westernblot analysis
confirms that ERK1/2 phosphorylation is
induced by PMA treatment and this induction
is mediated through PKC and MEK because
both GF109203X and U0126 treatments inhibit
PMA-induced ERK1/2 phosphorylation. Taken
together, these results suggest that both PKC
andMEK are required for PMA-induced ERK1/
2 phosphorylation andMGPmRNA expression.
However, the regulation of MGP by PMA and
ERKphosphorylation appears tobe complicated
and questions exist in answering some key
aspects of this regulation. For instance, PMA
can regulate MGP mRNA levels through phos-
phorylation of ERK, however, PMA does not
regulate Mgp promoter while a constitutively
active MEK does. Therefore, if PMA does
phosphorylate ERK, and ERK activation is
sufficient to activate Mgp promoter, why is
PMA unable to activate the MGP promoter?
As discussed earlier, an explanation for this
finding could be that PMAmost likely regulates
MGP expression through activation of ERK
through DNA elements that are not present in
the 748 bp Mgp promoter. Another explana-
tion would be that different ERK isoforms and/
or ERK substrates were activated by PMA
versus constitutively active MEK. Even though
the main cascade of ERK activation includes
Raf, MEK 1/2, and ERK, several alternative
spliced forms exist in different tiers. To date,
eight members of the ERK family have been
identified, ERK 1,2,3,4,5,6,7, and 8 [Bogoye-
vitch and Court, 2004] At least 160 substrates
have been discovered for ERK [Yoon and Seger,
2006]. These components enhance the complex-
ity of the ERK cascade and thereby the wide
variety of functions of ERK family proteins.
PTH signaling in osteoblasts is quite complex
and involves crosstalk between multiple path-
ways, that is, PKA, PKC, and ERK [Swarthout
et al., 2002]. For example, prolonged activation
of PKC by PMA significantly decreased PTH-
induced production of cAMP, an upstream
activator of PKA, in UMR106 osteoblastic cells
[Sugimoto et al., 1994]. However, brief exposure
to PMA augmented PTH-induced cAMP pro-
duction in these cells. In addition, PKA activa-
tion can inhibit ERK activity in bothMC3T3-E1
and UMR106 cells [Siddhanti et al., 1995;
Verheijen and Defize, 1995]. In addition to
cross-regulation, cooperation of these signaling
pathways to regulate PTH-responsive gene
expression has also been reported [Swarthout
et al., 2002]. For example, PTH induction of
collagenase-3 in differentiating osteoblasts
involves both PKAandPKCpathways [Winche-
ster et al., 1999]. PTH-mediated Smad-3 induc-
tion in MC3T3-E1 and UMR-106 osteoblastic
cells requires PKA as well as PKC signaling
[Sowa et al., 2003]. Consistent with our results,
Jiang et al. [2004] has recently shown that PKA,
PKC, and ERK are all important for PTH
induction of osteocalcin in MC3T3-E1 cells. To
date, PKA is considered the key pathway
leading to PTH-mediated activation of CREB,
AP-1, and RUNX2 transcription factors, and
thus to changes in gene expression in osteo-
blasts. Unlike PKA, the consequence of PKC
andERKactivation by PTH is just starting to be
understood. More studies are needed to inves-
tigate themolecular events following activation
of these pathways by PTH.
Here, we report that both PKA and ERK
pathways play significant roles in PTH regula-
tion of MGP. These results provide improved
Signaling Pathways in PTH Regulation of MGP 503
insight into the signaling mechanisms used by
PTH in osteoblasts as well as important clues
about regulation of MGP, to help determine
the transcription factor(s) and DNA binding
elements critical for PTH induction of MGP in
osteoblasts.
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